Acceptable strategies for dealing with hereditary breast/ovarian cancer risk.

@article{Eisinger1997AcceptableSF,
  title={Acceptable strategies for dealing with hereditary breast/ovarian cancer risk.},
  author={François Eisinger and Claire Julian Reynier and Françoise Chabal and Catherine Luquet and J-P. Moatti and Hagay Sobol},
  journal={Journal of the National Cancer Institute},
  year={1997},
  volume={89 10},
  pages={
          731
        }
}
Since the breast cancer genes BRCA1 and BRCA2 were identified, it has become possible to determine the gene carrier status in women. However, no conclusive data are available so far about the efficacy (1) of the three main strategies for managing hereditary breast and ovarian cancer, i.e., prophylactic surgery, screening, and chemoprevention with tamoxifen (2). In situations involving major uncertainty, the a priori acceptability of the available strategies is one of the main criteria used in… 
Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee.
TLDR
Although no scientific evidence is available, the Ad Hoc Committee feels that specific management is indispensable and advocates the use of defined and evaluated procedures, and participation in clinical trials.
Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.
  • L. Kaduri, M. Gibs, +7 authors T. Peretz
  • Medicine, Biology
    European journal of obstetrics, gynecology, and reproductive biology
  • 1999
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
TLDR
The use of these morphological features of BRCA1-BCs that are currently typed in clinical practice provides a helpful and cost-effective tool for those making decisions about genetic screening and makes it possible to identify gene carriers who would be overlooked using current criteria.
Factors associated with decisions about clinical BRCA1/2 testing.
TLDR
It is suggested that approximately half of eligible women choose to undergo clinical BRCA1/2 testing after participating in counseling, and women who undergo testing are also more interested in ovarian cancer risk information and less concerned about job and insurance discrimination.
Clinical management of BRCA1- and BRCA2-associated breast cancer.
  • S. Karp
  • Medicine, Biology
    Seminars in surgical oncology
  • 2000
TLDR
The issues related to establishing a diagnosis of inherited breast cancer, deciding which women are candidates for testing, the limitations of testing, and the predictive power of these tests are addressed.
Initial experiences of women from hereditary breast cancer families after bilateral prophylactic mastectomy: a retrospective study.
  • U. Josephson, M. Wickman, K. Sandelin
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2000
TLDR
Assessing 15 women's experience with the decision-making process prior to undergoing prophylactic bilateral mastectomy and immediate breast reconstruction found that they lacked psychological support from the different caregivers, and the result exceeded all patients' initial expectations.
Short Communication Factors Associated with Decisions about Clinical BRCA1/2 Testing 1
TLDR
It is suggested that approximately half of eligible women choose to undergo clinical BRCA1/ 2 testing after participating in counseling, and women who undergo testing are also more interested in ovarian cancer risk information and less concerned about job and insurance discrimination.
Disclosure to the family of breast/ovarian cancer genetic test results: patient's willingness and associated factors.
TLDR
The first step of the relatives' attendance to genetic counseling and the proband's willingness to disclose breast cancer genetic tests results was high in this study and was clearly dependent on the women's personal and emotional characteristics.
Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force
TLDR
The results of genetic testing could lead to prevention interventions for reducing risk or mortality in mutation carriers, and experts recommend earlier and more frequent cancer screening, chemoprevention, and prophylactic surgery.
Prognostic implications of cancer susceptibility genes: any news?
  • R. Scott, H. Sobol
  • Medicine, Biology
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 1999
TLDR
In this chapter several aspects of these inherited cancer predispositions will be discussed and compared with their equivalent sporadic disease counterparts.
...
1
2
...

References

SHOWING 1-8 OF 8 REFERENCES
Screening in breast cancer families: is it useful?
TLDR
Although surveillance programmes for hereditary cancers have been recommended for many years, there is still little or no evidence that surveillance will improve the prognosis, and prospective controlled studies are urgently needed to assess the value of the recommended screening protocols.
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
TLDR
Only a subset of HBOC family members are likely to request BRCA1 testing when available and rates of test use may be higher in persons of a higher socioeconomic status and those with more relatives affected with breast cancer.
Tamoxifen: trials, tribulations, and trade-offs.
TLDR
This study is noteworthy not only because it is the largest randomized experience reported to date, but also because it utilized a placebo control, which permits the accurate estimate of the increased risk in the tamoxifen-treated patients, since there should be no screening bias.
Report of the International Workshop on Screening for Breast Cancer.
BACKGROUND Over the past 30 years, eight major randomized controlled trials of breast cancer screening--with mammography and/or clinical breast examination--have been conducted. Results from several
Ovarian cancer: screening, treatment, and followup.
TLDR
There is no evidence available yet that the current screening modalities of CA 125 and transvaginal ultrasonography can be effectively used for widespread screening to reduce mortality from ovarian cancer nor that their use will result in decreased rather than increased morbidity and mortality.
NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.
  • Medicine
    JAMA
  • 1995
TLDR
There is no evidence available yet that the current screening modalities of CA-125 and transvaginal ultrasonography can be effectively used for widespread screening to reduce mortality from ovarian cancer nor that their use will result in decreased rather than increased morbidity and mortality.
lies: is it useful? Ann Med 1994;26:185-90
  • 1994